99 related articles for article (PubMed ID: 14579030)
21. Biologics in rheumatoid arthritis.
Sharma PK; Hota D; Pandhi P
J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
[TBL] [Abstract][Full Text] [Related]
22. Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology.
Patten C; Bush K; Rioja I; Morgan R; Wooley P; Trill J; Life P
Arthritis Rheum; 2004 Oct; 50(10):3334-45. PubMed ID: 15476226
[TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
Zhou H
J Clin Pharmacol; 2005 May; 45(5):490-7. PubMed ID: 15831771
[TBL] [Abstract][Full Text] [Related]
24. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.
Semerano L; Thiolat A; Minichiello E; Clavel G; Bessis N; Boissier MC
Expert Opin Investig Drugs; 2014 Jul; 23(7):979-99. PubMed ID: 24766460
[TBL] [Abstract][Full Text] [Related]
25. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
26. Vitaxin applied molecular evolution.
Mikecz K
Curr Opin Investig Drugs; 2000 Oct; 1(2):199-203. PubMed ID: 11249574
[TBL] [Abstract][Full Text] [Related]
27. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
28. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H; Kavanaugh A
Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
[TBL] [Abstract][Full Text] [Related]
29. [Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors. Grupo de Estudio de Nuevas Terapias de Enfermedades reumáticas (GENTE)].
Díaz-Jouanen E; Abud-Mendoza C; Garza-Elizondo MA; Medrano-Ramírez G; Burgos-Vargas R; Orozco-Alcalá JJ; Pacheco-Tena CF; Pineda C; Pozos-Espíndola JC; Ramos-Niembro F; Robles-San-Román M; Santana-Sahagún JE;
Rev Invest Clin; 2009; 61(3):252-66. PubMed ID: 19736814
[TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
Puéchal X; Miceli-Richard C; Mejjad O; Lafforgue P; Marcelli C; Solau-Gervais E; Steinfeld S; Villoutreix C; Trèves R; Mariette X; Guillevin L;
Ann Rheum Dis; 2008 Jun; 67(6):880-4. PubMed ID: 18037625
[TBL] [Abstract][Full Text] [Related]
32. Comparative overview of safety of the biologics in rheumatoid arthritis.
Khraishi M
J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
[TBL] [Abstract][Full Text] [Related]
33. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard?
Boers M
Arthritis Rheum; 2003 Jun; 48(6):1481-3. PubMed ID: 12794813
[No Abstract] [Full Text] [Related]
34. MFG-IRAP University of Pittsburgh.
Baragi VM
Curr Opin Investig Drugs; 2000 Oct; 1(2):194-8. PubMed ID: 11249573
[TBL] [Abstract][Full Text] [Related]
35. Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis.
Strand V
Z Rheumatol; 1998 Feb; 57(1):41-5. PubMed ID: 9566107
[No Abstract] [Full Text] [Related]
36. Psoriatic arthritis - treatment update.
Mease PJ
Bull NYU Hosp Jt Dis; 2011; 69(3):243-9. PubMed ID: 22035437
[No Abstract] [Full Text] [Related]
37. New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs.
Fye KH
Postgrad Med; 1999 Oct; 106(4):82-5, 88-90, 92. PubMed ID: 10533510
[TBL] [Abstract][Full Text] [Related]
38. [Early diagnosis and new therapeutic options. More power against rheumatoid arthritis].
Bischoff A
MMW Fortschr Med; 2003 Jan; 145(5):4-6. PubMed ID: 12619197
[No Abstract] [Full Text] [Related]
39. [Therapy with not yet approved drugs or for not yet approved indications].
Wollenhaupt J
Z Rheumatol; 2001 Dec; 60(6):450-2. PubMed ID: 11826739
[No Abstract] [Full Text] [Related]
40. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 4. Interleukin-1 inhibitor].
Yamasaki S; Kawakami A
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2985-90. PubMed ID: 22175142
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
